International Symposium

 

Advances in Systems Biology in Neurosciences

6. February 2015 in Geneva, SwitzerlandCampus Meeting announcement
Organised by the AgedBrainSYSBIO project and the SIB Swiss Institute of Bioinformatics
W
ith financial support from Novartis and Roche

Introduction

Alzheimer’s disease is characterized by diminishing memory and thinking skills, affecting as many as 8 million  Europeans, most over the age of 60. The causes of Alzheimer’s disease are still largely unknown, though they are likely a combination of genetic, environmental and other factors.

As part of ongoing research to better understand the complexities of the human brain, different European-funded FP7-HEALTH consortia such as AgedBrainSYSBIO (on systems biology, synapse and ageing) and SYNSYS (on systems biology and synapse), the European flagship Human Brain Project, Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Allen Institute for Brain Science in the US are embarking on efforts to unravel molecular mechanisms involved in brain functioning both in normal conditions and during ageing.
We expect that this meeting will generate novel interactions between leading groups in the field. Because of the increasing interest in ageing-related diseases such as neuropathologies, we expect the symposium to gather between 100 – 150 participants.
This symposium will bring together clinicians, biologists, bioinformaticians, statisticians, who will present the latest advances in the field of neuroscience, taking advantage of state-of-the-art approaches provided by omics-biotechnologies, supercomputers, neuroimaging, amongst others.

 

Programme:
SESSION I - Systems biology & neuroscience   
This session will focus on new path towards understanding the brain and building information technology

SESSION II - Systems biology, genome-wide association studies and neuronal diseases
This section aims at molecular analysis of synapse function, its dynamic modeling and their links with genetic architecture of neuronal diseases.
SESSION III - Systems biology, genome-wide association studies and ageing
The session will focus on the generation of a blueprint for the discovery of novel pathways and targets that enable rational strategies to design therapies for normal and pathological ageing.

 

Invited Speakers
Prof Arthur W. Toga, Center for Computational Biology, USC, Los Angeles, CA, USA
Prof Jane A Driver, Brigham and Women's Hospital, Boston, MA, USA
Dr. Ed Lein, Allen Institute for Brain Science, Seattle, WA, USA (to be confirmed)
Prof. Henry Markram, The Blue Brain Project EPFL, Lausanne, Switzerland (to be confirmed)
Prof. Jean-François Demonet, CHUV University Hospital, Lausanne, Switzerland
Prof. Seth Grant, Center for Neuroregeneration, University of Edinburgh, UK (to be confirmed)
Dr. Sean Hill, The Blue Brain Project EPFL, Lausanne, Switzerland

 

And with the participation of the following AgedBrainSYSBIO members
Dr. Yann Herault, IGBMC, Illkirch, France
Prof. James Adjaye, Institute for Stem Cell Research and Regenerative Medicine, University of Dusseldorf, Germany
Prof. Tal Pupko, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel  
Dr. Jérôme Dauvillier, CH Swiss-Prot & Vital-IT group, SIB, University of Lausanne, Switzerland
Dr. Nicolas Le Novère, Babraham Institute, Cambridge, United Kingdom
Prof. Michel Simonneau, INSERM U894,  Centre Psychiatrie & Neurosciences, Paris, France

 

Note: The number of participants is limited to 200 attendees. Places will be attributed on a first-come first-serve basis

 

 

Registration CLOSED

 

     

      Programme      Venue      Registration      Abstract & Poster Guidelines     

 

Accommodation

 

 

 

The symposium is funded by the European Commission through the AgedBrainSYSBIO project and received financial support from the Vital-IT/Swiss-Prot@SIB, Novartis and Roche.

 

Logo AgedBrainSysbio            european flag blueyellow standard              SIB          novartis-logo-copie 2        Roche-logo

 


Last update on 2016-07-22

AgedBrainSYSBIO has received funding from the European Union’s Seventh Framework Programme for research,
technological development and demonstration under grant agreement No 305299
european flag blueyellow standard